Allervie Clinical Research — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$121,980	43
2024	Research	$76,801	72
2023	Research	$89,268	7

Breakdown

Who paid Research payments · program years 2023–2025

Novartis Pharmaceuticals Corporation $98,769 6 payments
Pfizer Inc. $88,855 25 payments
CSL Behring $57,931 1 payment
Incyte Corporation $24,241 86 payments
AstraZeneca Pharmaceuticals LP $12,500 1 payment
Celgene Corporation $3,430 1 payment
Grifols Biologicals LLC $1,723 1 payment
Grifols Therapeutics LLC $600 1 payment

Studies the money was for Research payments · program years 2023–2025

A Phase 2 Randomized Doubleblind Placebocontrolled Study to Investigate the Efficacy and Safety of Pf07275315 and Pf07264660 in Adult Participants With Moderatesevere Atopic Dermatitis $85,318 23 payments
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy and Safety of Subcutaneous Administration of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema $57,931 1 payment
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal and Open-Label Extension Study Followed By Long-Term Open-Label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (Lou064) in Adult Chronic Spontaneous U $55,871 1 payment
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma $23,157 57 payments
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista $22,488 1 payment
Implementation of the US PRECISION AIRQT Asthma Checklist and Educational Resources PRECISION Program into Clinical Practice Using Telehealth and In Person Platforms $12,500 1 payment
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co $11,805 1 payment
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines $5,184 1 payment
A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study With A Doubleblind 52Week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo $3,537 2 payments
(CC-93538-AD-001) Phase IIB Study (GDMA) - A Phase 2, Multicenter, Global, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Cendakimab (CC-93538) in Adult Subjects with Moderate to Severe Atopic Der $3,430 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.